Vivimed Labs acquires privately held Klar Sehen

Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence specialty medicine areas.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Travelcafe
moneycontrol.com

Home » News » Business

Oct 03, 2011, 03.56 PM | Source: Moneycontrol.com

Vivimed Labs acquires privately held Klar Sehen

Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence specialty medicine areas.

Like this story, share it with millions of investors on M3

Vivimed Labs acquires privately held Klar Sehen

Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence specialty medicine areas.

Post Your Comments

Share Cancel

Vivimed Labs acquires privately held Klar Sehen
Moneycontrol Bureau

Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence in specialty medicine areas.

The financial terms of the deal were not disclosed.

The 30-year-old company operates in a niche ophthalmic segment and owns about 50 trademarks and brands like Renicol, Dexacort, Lysicon-V,  in eye care, Vivimed said Monday.

Klar Sehen has strong marketing presence in North East, Bihar and Andhra Pradesh, it said. It has manufacturing facilities at Kolkata and Hyderabad and also has arrangements to manufacture some of its products in Uttarakhand, and operates with over 150 medical sales professionals, Vivimed said.

Earlier last month Vivimed had completed the acquisition of Octtantis Nobel, a Hyderabad-based pharmaceutical marketing company.

Vivimed Labs shares were trading up 1.2% at Rs 247.50 on NSE on Monday.

Vivimed Labs stock price

On May 06, 2016, at 15:06 hrs Vivimed Labs was quoting at Rs 88.00, down Rs 0.65, or 0.73 percent. The 52-week high of the share was Rs 485.00 and the 52-week low was Rs 83.40.


The company's trailing 12-month (TTM) EPS was at Rs 1.57 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 56.05. The latest book value of the company is Rs 46.03 per share. At current value, the price-to-book value of the company is 1.91.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Vivimed Labs acquires privately held Klar Sehen

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login